[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345013-105":59,"doc-detail-345013-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","computational-design-of-a-tcr-based-bispecific-engager-targeting-cancerous-kras-g12v-mutations","Computational Design of a TCR-Based Bispecific Engager Targeting Cancerous KRAS G12V Mutations","","Bispecific T-cell engager (BiTE) immunotherapy redirects cytotoxic T cells to tumor cells, typically by dual binding to CD3 and an extracellular tumor antigen. Traditional BiTEs can cause off-tumor effects because they target antigens shared across variants. This study uses a computational design workflow to create two TCR-BiTEs incorporating a TCR that binds the KRAS G12V neoantigen, enabling specificity where no FDA-approved targeted therapy exists. The work reports two promising TCR-BiTE candidates selective for HLA:03:01 and HLA:11:01 and validates them using AlphaFold, free-energy estimation, and molecular dynamics, supporting a pipeline for other KRAS mutations.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/computational-design-of-a-tcr-based-bispecific-engager-targeting-cancerous-kras-g12v-mutations/345013/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/computational-design-of-a-tcr-based-bispecific-engager-targeting-cancerous-kras-g12v-mutations/345013.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem do traditional BiTEs face in targeting cancer variants?","Question",{"text":113,"@type":114},"Traditional BiTEs dual-bind CD3 and an extracellular tumor antigen, but off-tumor effects can occur because the targeted antigens may not be specific to certain cancer variants.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does this study’s TCR-BiTE design improve specificity for KRAS G12V?",{"text":118,"@type":114},"The proposed TCR-BiTEs incorporate a TCR that specifically binds the KRAS G12V neoantigen presented by particular HLA molecules, rather than relying on an scFv that targets a broader surface antigen.",{"name":120,"@type":111,"acceptedAnswer":121},"What methods were used to validate the TCR-BiTE structures?",{"text":122,"@type":114},"Validation combined AlphaFold tools, free energy estimation methods, and molecular dynamics analysis to assess and support the designed structures.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},345013,1790176951,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","This article is licensed under CC-BY-NC-ND 4.0   \n[http://pubs.acs.org/journal/acsodf](http://pubs.acs.org/journal/acsodf)  Article   \nComputational Design of a TCR-Based Bispecific Engager Targeting Cancerous KRAS G12V Mutations  \nNisarg Shah, Gargi Sharma, Vihaan Patel, Melinda Wu, Anishreddy Mummadi, Anya Taneja, Moksh Shah, Gia Bao Le, Madhav Krishna, and Harman Brah *  \n Cite This: ACS Omega 2026, 11, 17366−17380  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Bispecific T-cell engager (BiTE) therapy is a type of immunotherapy that redirects cytotoxic T cells to target tumor cells. Traditionally, a BiTE structure dual binds to the CD3 receptor on the T-cell surface and to the mutated antigen presented on the surface of the cancer cell as an extracellular protein. An example of this is blinatumomab, an FDA-approved BiTE structure for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). However, traditional BiTE complexes are at risk of off-tumor effects due to their targeting of cell surface antigens, which are not specific to certain cancer variants. In this study, we utilized a computational approach, an area that remains underdeveloped in current immunotherapy design, to design the initial structures oftwo TCR-BiTEs that consist of a single-chain variable fragment (scFv) in conjunction with a Tcell receptor (TCR) that binds specifically to the KRAS G12V neoantigen, which currently does not have any FDA-approved targeted therapy treatments. Ultimately, we present two promising  \nTCR-BiTEs that are specific to two different HLAs (HLA:03:01 and HLA:11:01) targeting KRAS G12V, serving as valuable starting points for further evaluation and design in vitro. We validated the design of our TCR-BiTE structures through AlphaFold tools, free energy estimation methods, and molecular dynamics analysis, thereby also providing a potential computational pipeline that can be applied in the design of TCR-BiTE structures targeting other mutations in addition to KRAS G12V.  \n■ INTRODUCTION  \nKRAS is one of the most frequently mutated oncogenes in colorectal cancer, nonsingle cell lung cancer, and pancreatic ductal adenocarcinoma.1  \nUnfortunately, the successful development of KRAS smallmolecule inhibitors was reliant on specific factors such as the high GTPase activity of KRAS G12C, which is not fully present in other KRAS mutant types, such as KRAS G12V.1 Asa result, the use of targeted therapy is limited in scope, and the need to develop treatments for the KRAS G12V mutation remains pressing.  \nIn response to this challenge, many alternatives to smallmolecule drugs are currently being investigated for KRAS treatment. One particular avenue that is being explored is immunotherapy, which utilizes the patient’s own T cells to eliminate malignant cells. Specifically, bispecific T-cell engager (BiTE) therapy has received acclaim due to its ability to enhance immune response by retargeting T cells to kill tumor cells via engineered bispecific antibodies.2 This unique ability of BiTEs to activate T cells bypasses the need to bind directly to the KRAS protein and also promotes T-cell activity in cancers that are naturally immunosuppressive due to the tumor microenvironment (TME).3  \nDespite these advantages, traditional BiTEs are limited by their structure. Composed of two single-chain variable fragments (scFvs) bound through a peptide sequence linker, BiTEs function by redirecting T cells to kill malignant cells,  \nengaging both the human leukocyte antigen (HLA) and CD3 molecules on immune receptors, and reducing its specificity. For instance, studies assessing the clinical efficacy of Blinatumomab, an FDA-approved BiTE for the treatment of B-acute lymphoblastic leukemia, found that blinatumomab tends to bind to noncancerous CD19 on healthy cells, pointing to a lack of specificity in binding.4  \nAs a potenti","cbCaipMBycXZchQQ","https://ap.wps.com/l/cbCaipMBycXZchQQ","pdf",13748812,15,"English","# Abstract\n## Background: BiTEs and off-tumor risk\n## Computational design of TCR-BiTEs for KRAS G12V\n## Validation workflow and outcomes","[{\"question\":\"What problem do traditional BiTEs face in targeting cancer variants?\",\"answer\":\"Traditional BiTEs dual-bind CD3 and an extracellular tumor antigen, but off-tumor effects can occur because the targeted antigens may not be specific to certain cancer variants.\"},{\"question\":\"How does this study’s TCR-BiTE design improve specificity for KRAS G12V?\",\"answer\":\"The proposed TCR-BiTEs incorporate a TCR that specifically binds the KRAS G12V neoantigen presented by particular HLA molecules, rather than relying on an scFv that targets a broader surface antigen.\"},{\"question\":\"What methods were used to validate the TCR-BiTE structures?\",\"answer\":\"Validation combined AlphaFold tools, free energy estimation methods, and molecular dynamics analysis to assess and support the designed structures.\"}]","Computational Design of a TCR-Based Bispecific Engager Targeting Cancerous KRAS G12V Mutations | PDF",1790056211,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eefc8bd7a4965e8cc988f42fcdaaea1.webp",983,1296,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/395327fc58fab63e8ff7aade9fee2f5b.webp",982,1295,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a2de99b33052ee403195a466ce5eba1.webp",981,1293,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaeab0f4b05630427738a0269a8bd2d1.webp",980,1292]